Meta-Analysis Questions Routine Use of Oral Antihistamines for Atopic Dermatitis
Key Clinical Summary
Oral H1 Antihistamines Offer Minimal Benefit in Atopic Dermatitis
-
A systematic review and network meta-analysis included 47 randomized trials and 6,230 children and adults, predominantly with moderate-to-severe atopic dermatitis, evaluating add-on antihistamines and related therapies.
-
Add-on H1 antihistamines modestly reduced objective SCORAD (mean difference, −1.87; 95% credible interval, −3.47 to −0.27) and itch (−0.89/10; 95% credible interval, −1.41 to −0.37), below predefined thresholds for clinical importance.
-
Evidence suggested little benefit for sleep or exacerbations; first-generation agents probably increased cognitive impairment. The authors advised against routine antihistamine use in atopic dermatitis management.
Adding oral H1 antihistamines to standard treatment for atopic dermatitis (AD) provides only minimal improvements in disease severity and itch while increasing the risk of adverse effects with first-generation agents, according to a systematic review and network meta-analysis of randomized trials.
Investigators searched MedlineAto, Embase, CENTRAL, and US Food and Drug Administration and European Medicines Agency databases through May 5, 2025. The analysis included 47 randomized trials enrolling 6230 children and adults with predominantly moderate-to-severe AD. The review evaluated oral H1 antihistamines, H2 blockers, mast cell stabilizers, and combination therapies as add-on treatments.
Compared with placebo, first- and second-generation H1 antihistamines were associated with statistically significant reductions in objective AD severity and itch. However, the magnitude of benefit fell below established thresholds for clinical importance.
With moderate-certainty evidence, add-on H1 antihistamines reduced objective SCORAD scores by a mean difference of -1.87 (95% credible interval, -3.47 to -0.27) and itch severity by -0.89 points on a 10-point numerical rating scale (95% credible interval, -1.41 to -0.37). Both improvements were substantially smaller than the predefined minimal important differences.
The analysis also found little evidence that antihistamines improve other clinically relevant outcomes. With low-certainty evidence, the studied interventions “may not improve sleep disturbance or reduce atopic dermatitis exacerbations.”
Safety findings differed between antihistamine classes. First-generation H1 antihistamines probably increased cognitive impairment and may increase treatment discontinuation because of adverse events. In contrast, cognitive impairment risk varied among second-generation agents, ranging from no additional cases with loratadine to small increases with levocetirizine and cetirizine.
The authors concluded that “adding H1 antihistamines probably results in a clinically unimportant reduction in atopic dermatitis severity and itch severity, and may not reduce sleep disturbance or atopic dermatitis exacerbations.” They further noted that “these findings provide evidence against routine antihistamine use in atopic dermatitis management and will inform updated clinical guidelines.”
Reference
Chu AWL, Wen A, Guyatt GH, et al. Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials. BMJ. 2026;394:e100163. Published online July 29, 2026. doi:10.1136/bmj-2026-100163
